Preliminary Results of a Phase Ii Study of Weekly Cabazitaxel in "Unfit" Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients Progressing After Docetaxel Treatment (Sogug-Cabasem Trial)

Pérez-Valderrama, Begoña; Mellado, Begoña; Juan, María José; Fernández, O.; Fernández-Parra, E.; Olza, María Ochoa de; Castellano, Daniel; Anido, Urbano; Domènech, Montserrat; Hernando, Susana; Arija, J.A. Arranz; Caballero, Cristina; Durán, Ignacio; Campayo, Marc; Chilet, M.R.; Climent, Miguel Ángel

doi:10.1093/annonc/mdu336.31

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to point out that it is safe for elderly patients to receive cabazitaxel taking into account that they are fit for chemotherapy [28]. In this regard, there is an ongoing study that focuses on the tolerability and efficacy of weekly cabazitaxel in unfit CRPC patients who progressed to docetaxel [29]. It is important to emphasize, as has already been mentioned, that, in relation to the cabazitaxel hematological toxicity which occurred in the TROPIC study, the use of primary prophylaxis with colony-stimulating factors was not permitted; however, with its more frequent use in daily clinical practice, the incidence of neutropenia has decreased notably [30].…”

Section: Taxanes (Cabazitaxel) After Docetaxel Progressionmentioning

confidence: 99%

Role of taxanes in advanced prostate cancer

Cassinello

Rodríguez

Aparicio³

2016

Clin Transl Oncol

View full text Add to dashboard Cite

Advanced prostate cancer is an androgen-dependent disease for which the initial treatment is an androgen deprivation maneuver. However, some primary resistances to hormonal treatment occur with increasing incidence throughout the evolution of the disease. The taxanes, docetaxel and cabazitaxel, exert their action at multiple levels at the tumor cell: besides inhibiting the mitosis and inducing the cell death, they induce the nuclear accumulation of FOXO1, a potent nuclear factor that acts against the activation of androgen receptor inhibiting the transcription of AR-V7 variant associated with the development of resistances to abiraterone and enzalutamide. Docetaxel, as first-line therapy, and cabazitaxel, as second-line therapy, have demonstrated to increase the survival in castration-resistant prostate cancer. The results from last studies either on high-risk localized disease or on androgen-sensitive tumors demonstrate the increasing role of taxanes at earlier states of prostate cancer.

show abstract

Section: Taxanes (Cabazitaxel) After Docetaxel Progressionmentioning

confidence: 99%